NEW

Johnson & Johnson to Acquire Shockwave Medical

Johnson & Johnson and Shockwave Medical, Inc. today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335 per share in cash, corresponding to an enterprise value of...

Medline Expands Catheter Portfolio

Medline and Consure Medical have announced a new agreement for Medline to exclusively distribute the QiVi MEC male external urine management device to help guard against catheter-associated urinary tract infections (CAUTI) and incontinence-associated dermatitis (IAD)....

FDA Clears Single-use Flexible Ureteroscope

Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced U.S. FDA 510(k) clearance of its first single-use ureteroscope system, RenaFlex™, with full market availability to be announced at a later...

Brainlab, Fujifilm Offer Advanced Neurosurgery Capabilities

FUJIFILM Healthcare Americas Corporation and Brainlab recently announced that Brainlab will be the exclusive U.S. distributor of ARIETTA Precision Ultrasound for neurosurgery applications to be utilized with Brainlab’s surgical navigation systems. ARIETTA Precision,...

Getinge Group appoints new President of Acute Care Therapies Business Category Unit

Getinge Group has appointed Jens Viebke as the new President of the Acute Care Therapies Business Category Unit. Viebke will be a member of the Getinge Group Executive Team and succeeds Heinz Jacqui who will step down from his current position after four years with the group. Acute care therapies is one of Getinge’s three business category units and is responsible for developing technologies and solutions for cardiac, pulmonary and vascular therapies and products and therapies for intensive care.

The group has made significant investments in quality management systems in recent years, particularly in areas related to the acute care therapies business category unit.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X